Market Research Logo

Haemoglobinopathies - Global Market Outlook (2016-2022)

Haemoglobinopathies - Global Market Outlook (2016-2022)

According to Stratistics MRC, the Global Hemoglobinopathie market is accounted for $4.6 billion in 2015 and is expected to reach $8.99 billion by 2022 growing at a CAGR of 10.0% from 2015 to 2022. Increasing incidences of hemoglobin disorders with strong product portfolio for sickle cell anemia such as HQK-1001 and Luspatercept, government’s awareness programs and advanced diagnostics and therapeutics will fuel the market growth. Research & development and growth across developed and developing economies will provide opportunity for the market growth. Instrumentation cost and expertise required for LC MS/MS, molecular identification of the alpha and beta chain mutations are some of the factors that impede the market growth.

Hydroxyurea was one of the dominating segments followed by Thalassemia and is estimated to grow at lucrative growth rate. Blood tests and pre-implant genetic testing is anticipated to grow further during forecast period. The market for blood transfusion was the largest with revenues in therapeutic segment. North America dominated the overall market. Africa, Asia Pacific and the Mediterranean regions are projected to show profitable growth.

Some of the key players in global Hemoglobinopathie market are Gamida Cell,Alnylam Pharmaceuticals, Biogen Idec, Genetix Pharmaceuticals, Global Blood Therapeutics Inc., Pfizer Inc., Mast Therapeutics, Emmaus Life Sciences, Inc., Prolong Pharmaceuticals, Celgene Corporation, HemaQuest Pharmaceuticals, Sangamo BioSciences Inc, Cancer Therapeutics CRC Pty Ltd, Datar Genetics Limited, Optinova Ab, Anthera Pharmaceuticals and AcceleronPharma.

Disorders Covered:
Sickle Cell Disease
Haemoglobin variants diseases
Haemoglobin C disease
Haemoglobin S-C disease
Thalassemia
Drugs Covered:
NiCord
ZFP Transcription Factors
ALN-TMP
Drug Targeting PRMT5
Drug Targeting Protein Arginine Methyltransferase 5
Diagnosis Covered:
Genetic Testing
Blood Testing
Pre-implantation Genetic Diagnosis
Prenatal Genetic Testing
Haemoglobin Electrophoresis
Therapies Covered:
Iron Chelation Therapy
Blood Transfusion
Hydroxyurea
Bone Marrow Transplant
Regions Covered:
North America
US
Canada
Mexico
Europe
Germany
France
Italy
UK
Spain
Rest of Europe
Asia Pacific
Japan
China
India
Australia
New Zealand
Rest of Asia Pacific
Rest of the World
Middle East
Brazil
Argentina
South Africa
Egypt

What our report offers:
Market share assessments for the regional and country level segments
Market share analysis of the top industry players
Strategic recommendations for the new entrants
Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements


1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.7 Emerging markets
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Haemoglobinopathies Market, By Disorder
5.1 Introduction
5.2 Sickle Cell Disease
5.3 Haemoglobin variants diseases
5.3.1 Haemoglobin C disease
5.3.2 Haemoglobin S-C disease
5.4 Thalassemia
5.4.1 Alpha Thalassemia
5.4.2 Beta Thalassemia
6 Global Haemoglobinopathies Market, By Drug
6.1 Introduction
6.2 NiCord
6.3 ZFP Transcription Factors
6.4 ALN-TMP
6.5 Drug Targeting PRMT5
6.6 Drug Targeting Protein Arginine Methyltransferase 5
7 Global Haemoglobinopathies Market, By Diagnosis
7.1 Introduction
7.2 Genetic Testing
7.3 Blood Testing
7.4 Pre-implantation Genetic Diagnosis
7.5 Prenatal Genetic Testing
7.6 Haemoglobin Electrophoresis
8 Global Haemoglobinopathies Market, By Therapy
8.1 Introduction
8.2 Iron Chelation Therapy
8.3 Blood Transfusion
8.4 Hydroxyurea
8.5 Bone Marrow Transplant
9 Global Haemoglobinopathies Market, By Geography
9.1 North America
9.1.1 US
9.1.2 Canada
9.1.3 Mexico
9.2 Europe
9.2.1 Germany
9.2.2 France
9.2.3 Italy
9.2.4 UK
9.2.5 Spain
9.2.9 Rest of Europe
9.3 Asia Pacific
9.3.1 Japan
9.3.2 China
9.3.3 India
9.3.4 Australia
9.3.5 New Zealand
9.3.9 Rest of Asia Pacific
9.4 Rest of the World
9.4.1 Middle East
9.4.2 Brazil
9.4.3 Argentina
9.4.4 South Africa
9.4.5 Egypt
10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 Company Profiling
11.1 Gamida Cell
11.2 Alnylam Pharmaceuticals
11.3 Biogen Idec
11.4 Genetix Pharmaceuticals
11.5 Global Blood Therapeutics Inc.
11.6 Pfizer Inc.
11.7 Mast Therapeutics
11.8 Emmaus Life Sciences, Inc.
11.9 Prolong Pharmaceuticals
11.10 Celgene Corporation
11.11 HemaQuest Pharmaceuticals
11.12 Sangamo BioSciences Inc
11.13 Cancer Therapeutics CRC Pty Ltd
11.14 Datar Genetics Limited
11.15 Optinova Ab
11.16 Anthera Pharmaceuticals
11.17 AcceleronPharma
List of Tables
Table 1 Global Haemoglobinopathies Market Analysis, by Region, (2013-2022) ($MN)
Table 2 Global Haemoglobinopathies Market Analysis, by Disorder, (2013-2022) ($MN)
Table 3 Global Haemoglobinopathies Market Analysis, by Sickle Cell Disease, (2013-2022) ($MN)
Table 4 Global Haemoglobinopathies Market Analysis, by Haemoglobin variants diseases, (2013-2022) ($MN)
Table 5 Global Haemoglobinopathies Market Analysis, by Haemoglobin C disease, (2013-2022) ($MN)
Table 6 Global Haemoglobinopathies Market Analysis, by Haemoglobin S-C disease, (2013-2022) ($MN)
Table 7 Global Haemoglobinopathies Market Analysis, by Thalassemia, (2013-2022) ($MN)
Table 8 Global Haemoglobinopathies Market Analysis, by Alpha Thalassemia, (2013-2022) ($MN)
Table 9 Global Haemoglobinopathies Market Analysis, by Beta Thalassemia, (2013-2022) ($MN)
Table 10 Global Haemoglobinopathies Market Analysis, by Drug, (2013-2022) ($MN)
Table 11 Global Haemoglobinopathies Market Analysis, by NiCord, (2013-2022) ($MN)
Table 12 Global Haemoglobinopathies Market Analysis, by ZFP Transcription Factors, (2013-2022) ($MN)
Table 13 Global Haemoglobinopathies Market Analysis, by ALN-TMP, (2013-2022) ($MN)
Table 14 Global Haemoglobinopathies Market Analysis, by Drug Targeting PRMT5, (2013-2022) ($MN)
Table 15 Global Haemoglobinopathies Market Analysis, by Drug Targeting Protein Arginine Methyltransferase 5, (2013-2022) ($MN)
Table 16 Global Haemoglobinopathies Market Analysis, by Diagnosis, (2013-2022) ($MN)
Table 17 Global Haemoglobinopathies Market Analysis, by Genetic Testing, (2013-2022) ($MN)
Table 18 Global Haemoglobinopathies Market Analysis, by Blood Testing, (2013-2022) ($MN)
Table 19 Global Haemoglobinopathies Market Analysis, by Pre-implantation Genetic Diagnosis, (2013-2022) ($MN)
Table 20 Global Haemoglobinopathies Market Analysis, by Prenatal Genetic Testing, (2013-2022) ($MN)
Table 21 Global Haemoglobinopathies Market Analysis, by Haemoglobin Electrophoresis, (2013-2022) ($MN)
Table 22 Global Haemoglobinopathies Market Analysis, by Therapy, (2013-2022) ($MN)
Table 23 Global Haemoglobinopathies Market Analysis, by Iron Chelation Therapy, (2013-2022) ($MN)
Table 24 Global Haemoglobinopathies Market Analysis, by Blood Transfusion, (2013-2022) ($MN)
Table 25 Global Haemoglobinopathies Market Analysis, by Hydroxyurea, (2013-2022) ($MN)
Table 26 Global Haemoglobinopathies Market Analysis, by Bone Marrow Transplant, (2013-2022) ($MN)
Table 27 North America Haemoglobinopathies Market Analysis, by Country, (2013-2022) ($MN)
Table 28 North America Haemoglobinopathies Market Analysis, by Disorder, (2013-2022) ($MN)
Table 29 North America Haemoglobinopathies Market Analysis, by Sickle Cell Disease, (2013-2022) ($MN)
Table 30 North America Haemoglobinopathies Market Analysis, by Haemoglobin variants diseases, (2013-2022) ($MN)
Table 31 North America Haemoglobinopathies Market Analysis, by Haemoglobin C disease, (2013-2022) ($MN)
Table 32 North America Haemoglobinopathies Market Analysis, by Haemoglobin S-C disease, (2013-2022) ($MN)
Table 33 North America Haemoglobinopathies Market Analysis, by Thalassemia, (2013-2022) ($MN)
Table 34 North America Haemoglobinopathies Market Analysis, by Alpha Thalassemia, (2013-2022) ($MN)
Table 35 North America Haemoglobinopathies Market Analysis, by Beta Thalassemia, (2013-2022) ($MN)
Table 36 North America Haemoglobinopathies Market Analysis, by Drug, (2013-2022) ($MN)
Table 37 North America Haemoglobinopathies Market Analysis, by NiCord, (2013-2022) ($MN)
Table 38 North America Haemoglobinopathies Market Analysis, by ZFP Transcription Factors, (2013-2022) ($MN)
Table 39 North America Haemoglobinopathies Market Analysis, by ALN-TMP, (2013-2022) ($MN)
Table 40 North America Haemoglobinopathies Market Analysis, by Drug Targeting PRMT5, (2013-2022) ($MN)
Table 41 North America Haemoglobinopathies Market Analysis, by Drug Targeting Protein Arginine Methyltransferase 5, (2013-2022) ($MN)
Table 42 North America Haemoglobinopathies Market Analysis, by Diagnosis, (2013-2022) ($MN)
Table 43 North America Haemoglobinopathies Market Analysis, by Genetic Testing, (2013-2022) ($MN)
Table 44 North America Haemoglobinopathies Market Analysis, by Blood Testing, (2013-2022) ($MN)
Table 45 North America Haemoglobinopathies Market Analysis, by Pre-implantation Genetic Diagnosis, (2013-2022) ($MN)
Table 46 North America Haemoglobinopathies Market Analysis, by Prenatal Genetic Testing, (2013-2022) ($MN)
Table 47 North America Haemoglobinopathies Market Analysis, by Haemoglobin Electrophoresis, (2013-2022) ($MN)
Table 48 North America Haemoglobinopathies Market Analysis, by Therapy, (2013-2022) ($MN)
Table 49 North America Haemoglobinopathies Market Analysis, by Iron Chelation Therapy, (2013-2022) ($MN)
Table 50 North America Haemoglobinopathies Market Analysis, by Blood Transfusion, (2013-2022) ($MN)
Table 51 North America Haemoglobinopathies Market Analysis, by Hydroxyurea, (2013-2022) ($MN)
Table 52 North America Haemoglobinopathies Market Analysis, by Bone Marrow Transplant, (2013-2022) ($MN)
Table 53 Europe Haemoglobinopathies Market Analysis, by Country, (2013-2022) ($MN)
Table 54 Europe Haemoglobinopathies Market Analysis, by Disorder, (2013-2022) ($MN)
Table 55 Europe Haemoglobinopathies Market Analysis, by Sickle Cell Disease, (2013-2022) ($MN)
Table 56 Europe Haemoglobinopathies Market Analysis, by Haemoglobin variants diseases, (2013-2022) ($MN)
Table 57 Europe Haemoglobinopathies Market Analysis, by Haemoglobin C disease, (2013-2022) ($MN)
Table 58 Europe Haemoglobinopathies Market Analysis, by Haemoglobin S-C disease, (2013-2022) ($MN)
Table 59 Europe Haemoglobinopathies Market Analysis, by Thalassemia, (2013-2022) ($MN)
Table 60 Europe Haemoglobinopathies Market Analysis, by Alpha Thalassemia, (2013-2022) ($MN)
Table 61 Europe Haemoglobinopathies Market Analysis, by Beta Thalassemia, (2013-2022) ($MN)
Table 62 Europe Haemoglobinopathies Market Analysis, by Drug, (2013-2022) ($MN)
Table 63 Europe Haemoglobinopathies Market Analysis, by NiCord, (2013-2022) ($MN)
Table 64 Europe Haemoglobinopathies Market Analysis, by ZFP Transcription Factors, (2013-2022) ($MN)
Table 65 Europe Haemoglobinopathies Market Analysis, by ALN-TMP, (2013-2022) ($MN)
Table 66 Europe Haemoglobinopathies Market Analysis, by Drug Targeting PRMT5, (2013-2022) ($MN)
Table 67 Europe Haemoglobinopathies Market Analysis, by Drug Targeting Protein Arginine Methyltransferase 5, (2013-2022) ($MN)
Table 68 Europe Haemoglobinopathies Market Analysis, by Diagnosis, (2013-2022) ($MN)
Table 69 Europe Haemoglobinopathies Market Analysis, by Genetic Testing, (2013-2022) ($MN)
Table 70 Europe Haemoglobinopathies Market Analysis, by Blood Testing, (2013-2022) ($MN)
Table 71 Europe Haemoglobinopathies Market Analysis, by Pre-implantation Genetic Diagnosis, (2013-2022) ($MN)
Table 72 Europe Haemoglobinopathies Market Analysis, by Prenatal Genetic Testing, (2013-2022) ($MN)
Table 73 Europe Haemoglobinopathies Market Analysis, by Haemoglobin Electrophoresis, (2013-2022) ($MN)
Table 74 Europe Haemoglobinopathies Market Analysis, by Therapy, (2013-2022) ($MN)
Table 75 Europe Haemoglobinopathies Market Analysis, by Iron Chelation Therapy, (2013-2022) ($MN)
Table 76 Europe Haemoglobinopathies Market Analysis, by Blood Transfusion, (2013-2022) ($MN)
Table 77 Europe Haemoglobinopathies Market Analysis, by Hydroxyurea, (2013-2022) ($MN)
Table 78 Europe Haemoglobinopathies Market Analysis, by Bone Marrow Transplant, (2013-2022) ($MN)
Table 79 Asia Pacific Haemoglobinopathies Market Analysis, by Country, (2013-2022) ($MN)
Table 80 Asia Pacific Haemoglobinopathies Market Analysis, by Disorder, (2013-2022) ($MN)
Table 81 Asia Pacific Haemoglobinopathies Market Analysis, by Sickle Cell Disease, (2013-2022) ($MN)
Table 82 Asia Pacific Haemoglobinopathies Market Analysis, by Haemoglobin variants diseases, (2013-2022) ($MN)
Table 83 Asia Pacific Haemoglobinopathies Market Analysis, by Haemoglobin C disease, (2013-2022) ($MN)
Table 84 Asia Pacific Haemoglobinopathies Market Analysis, by Haemoglobin S-C disease, (2013-2022) ($MN)
Table 85 Asia Pacific Haemoglobinopathies Market Analysis, by Thalassemia, (2013-2022) ($MN)
Table 86 Asia Pacific Haemoglobinopathies Market Analysis, by Alpha Thalassemia, (2013-2022) ($MN)
Table 87 Asia Pacific Haemoglobinopathies Market Analysis, by Beta Thalassemia, (2013-2022) ($MN)
Table 88 Asia Pacific Haemoglobinopathies Market Analysis, by Drug, (2013-2022) ($MN)
Table 89 Asia Pacific Haemoglobinopathies Market Analysis, by NiCord, (2013-2022) ($MN)
Table 90 Asia Pacific Haemoglobinopathies Market Analysis, by ZFP Transcription Factors, (2013-2022) ($MN)
Table 91 Asia Pacific Haemoglobinopathies Market Analysis, by ALN-TMP, (2013-2022) ($MN)
Table 92 Asia Pacific Haemoglobinopathies Market Analysis, by Drug Targeting PRMT5, (2013-2022) ($MN)
Table 93 Asia Pacific Haemoglobinopathies Market Analysis, by Drug Targeting Protein Arginine Methyltransferase 5, (2013-2022) ($MN)
Table 94 Asia Pacific Haemoglobinopathies Market Analysis, by Diagnosis, (2013-2022) ($MN)
Table 95 Asia Pacific Haemoglobinopathies Market Analysis, by Genetic Testing, (2013-2022) ($MN)
Table 96 Asia Pacific Haemoglobinopathies Market Analysis, by Blood Testing, (2013-2022) ($MN)
Table 97 Asia Pacific Haemoglobinopathies Market Analysis, by Pre-implantation Genetic Diagnosis, (2013-2022) ($MN)
Table 98 Asia Pacific Haemoglobinopathies Market Analysis, by Prenatal Genetic Testing, (2013-2022) ($MN)
Table 99 Asia Pacific Haemoglobinopathies Market Analysis, by Haemoglobin Electrophoresis, (2013-2022) ($MN)
Table 100 Asia Pacific Haemoglobinopathies Market Analysis, by Therapy, (2013-2022) ($MN)
Table 101 Asia Pacific Haemoglobinopathies Market Analysis, by Iron Chelation Therapy, (2013-2022) ($MN)
Table 102 Asia Pacific Haemoglobinopathies Market Analysis, by Blood Transfusion, (2013-2022) ($MN)
Table 103 Asia Pacific Haemoglobinopathies Market Analysis, by Hydroxyurea, (2013-2022) ($MN)
Table 104 Asia Pacific Haemoglobinopathies Market Analysis, by Bone Marrow Transplant, (2013-2022) ($MN)
Table 105 RoW Haemoglobinopathies Market Analysis, by Country, (2013-2022) ($MN)
Table 106 RoW Haemoglobinopathies Market Analysis, by Disorder, (2013-2022) ($MN)
Table 107 RoW Haemoglobinopathies Market Analysis, by Sickle Cell Disease, (2013-2022) ($MN)
Table 108 RoW Haemoglobinopathies Market Analysis, by Haemoglobin variants diseases, (2013-2022) ($MN)
Table 109 RoW Haemoglobinopathies Market Analysis, by Haemoglobin C disease, (2013-2022) ($MN)
Table 110 RoW Haemoglobinopathies Market Analysis, by Haemoglobin S-C disease, (2013-2022) ($MN)
Table 111 RoW Haemoglobinopathies Market Analysis, by Thalassemia, (2013-2022) ($MN)
Table 112 RoW Haemoglobinopathies Market Analysis, by Alpha Thalassemia, (2013-2022) ($MN)
Table 113 RoW Haemoglobinopathies Market Analysis, by Beta Thalassemia, (2013-2022) ($MN)
Table 114 RoW Haemoglobinopathies Market Analysis, by Drug, (2013-2022) ($MN)
Table 115 RoW Haemoglobinopathies Market Analysis, by NiCord, (2013-2022) ($MN)
Table 116 RoW Haemoglobinopathies Market Analysis, by ZFP Transcription Factors, (2013-2022) ($MN)
Table 117 RoW Haemoglobinopathies Market Analysis, by ALN-TMP, (2013-2022) ($MN)
Table 118 RoW Haemoglobinopathies Market Analysis, by Drug Targeting PRMT5, (2013-2022) ($MN)
Table 119 RoW Haemoglobinopathies Market Analysis, by Drug Targeting Protein Arginine Methyltransferase 5, (2013-2022) ($MN)
Table 120 RoW Haemoglobinopathies Market Analysis, by Diagnosis, (2013-2022) ($MN)
Table 121 RoW Haemoglobinopathies Market Analysis, by Genetic Testing, (2013-2022) ($MN)
Table 122 RoW Haemoglobinopathies Market Analysis, by Blood Testing, (2013-2022) ($MN)
Table 123 RoW Haemoglobinopathies Market Analysis, by Pre-implantation Genetic Diagnosis, (2013-2022) ($MN)
Table 124 RoW Haemoglobinopathies Market Analysis, by Prenatal Genetic Testing, (2013-2022) ($MN)
Table 125 RoW Haemoglobinopathies Market Analysis, by Haemoglobin Electrophoresis, (2013-2022) ($MN)
Table 126 RoW Haemoglobinopathies Market Analysis, by Therapy, (2013-2022) ($MN)
Table 127 RoW Haemoglobinopathies Market Analysis, by Iron Chelation Therapy, (2013-2022) ($MN)
Table 128 RoW Haemoglobinopathies Market Analysis, by Blood Transfusion, (2013-2022) ($MN)
Table 129 RoW Haemoglobinopathies Market Analysis, by Hydroxyurea, (2013-2022) ($MN)
Table 130 RoW Haemoglobinopathies Market Analysis, by Bone Marrow Transplant, (2013-2022) ($MN)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report